ATP6V1E1

Across TCGA pan-cancer cohorts, ATP6V1E1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ATP6V1E1 data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ATP6V1E1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ATP6V1E1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, SKCM, and HNSC are the cancer types where ATP6V1E1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.068	0.812	<.001	36	view →
SKCM	OS	Median	All	0.245	0.781	.008	15	view →
HNSC	OS	Median	IV	0.013	0.733	<.001	12	view →
UCEC	DFS	Median	II,III,IV	1.000	0.443	.039	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ATP6V1E1–LUAD (OS)

Open the LUAD breakdown →